In addition, studies by Yuan et al. (9) and C. Achour et al. (61) also showed that METTL3 knockdown can suppress MYC protein levels, respectively, which is also common in several other cancers, such as AML, gastric cancer, colorectal cancer, and bladder cancer (50–53). Here, METTL3 is linked to acute myeloid leukemia.